Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Event Details


Superbugs & Superdrugs USA

The sell-out conference series returns with Superbugs USA for industry leaders to strengthen their antibiotic pipeline, network and exchange novel solutions to combat the growing global threat of AMR

Add this event to your calendar: iCal   Google Calendar


Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group are thrilled to announce the return of Superbugs & Superdrugs USA which arrives to Iselin, New Jersey on NOV 13-14 2017.

Antimicrobial resistance has sparked an urgency in the development of new drugs as the industry strives for novel solutions to fight infectious diseases. Innovation and collaboration is requested at every level making Superbugs & Superdrugs USA, the perfect platform to strengthen knowledge in key principles such as funding incentives and global strategy, whilst honing in on clinical developments in areas such as immunotherapy, toxoid based vaccines and anti-body drug conjugates.

This is critical time for AMR experts, government bodies and industry leaders, to come together and share ideas on the latest developments in treatment and prevention.

Speakers Include:

Anthony Simon Lynch, Senior Scientific Dir, Janssen
William Weiss, Dir, Pre-Clinical Services, UNT Health Science Center
John Rex, CMO & Dir, F2G; Chief Strategy Officer, CARB-X
Christopher Houchens, Branch Chief, Antibacterials Program, BARDA
Annaliesa Anderson, VP & CSO Bacterial Vaccines, Pfizer
Olga Danilchanka, Microbiome Lead, Merck
Christopher McMaster, President & CEO, DemovaMed
Obadiah Plante, Dir of Research, Visterrra
Tim Opperman, Senior Research Scientist, Microbiotix
Ken Stover, Senior Dir, Infectious Diseases and Vaccines, MedImmune
Mike Westby, Dir, Centauri Therapeutics


Guidelines for successfully seeking funding and partnership with updates on the CARB-X initiative
Understand the importance of supporting natural immunity and the microbiome for reducing infection from resistant bacteria
New insight into treating gram-negative infections
Explore emerging and non-traditional approaches to antimicrobial drug development, including biologic drugs and combination treatment


Conference + Workshop: USD 2398 Conference Only: USD 1899


Teri Arri

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.